Boston Scientific (NYSE:BSX) beat analyst expectations on both Q1 earnings and revenue and raised its full-year forecast, sending shares up over 5% intra-day today.

The medical device maker reported adjusted earnings of $0.75 per share for the first quarter, topping the $0.67 consensus. Revenue surged 20.9% year-over-year to $4.66 billion, also beating estimates.

Growth was strong across the board. Cardiovascular sales soared 26.2% to $3.09 billion, fueled by continued demand for innovative heart and vascular treatments. The MedSurg division also delivered solid results, with revenue rising 11.7% to $1.58 billion.

Buoyed by the strong start, Boston Scientific raised its full-year 2025 earnings guidance to a range of $2.87 to $2.94 per share, up from the prior range of $2.80 to $2.87. The company also expects organic revenue growth between 12% and 14% for the year, reflecting sustained momentum across its product lines.

For the second quarter, the company projects organic revenue growth of 13% to 15% and adjusted earnings per share between $0.71 and $0.73, reinforcing confidence in its growth trajectory and operational strength.